SAP's Signavio hit with function injunction in Germany

A Munich court enjoined SAP from providing a specific Signavio Process Intelligence feature in Germany, finding that it infringed a Celonis patent on measuring lead time between process stages. The ruling does not apply to Signavio as a whole or affect S/4HANA Cloud migrations; SAP has appealed and separately challenged the patent’s validity. The decision is one of several ongoing disputes between the companies, including US cases, with a trial in Celonis’s California case scheduled for September 2027.

Analysis

The near-term economic exposure looks more like a product and execution risk than a material earnings shock: the ruling is confined to one feature in Germany, and SAP says the wider product and S/4HANA migrations remain available. The market-relevant question is whether SAP can replace or disable the function without weakening Signavio’s usefulness or slowing RISE conversion conversations—not the injunction alone. If a workaround is straightforward, direct revenue exposure may be limited; if not, the risk extends to customer confidence in SAP’s migration toolkit and could create an opening for Celonis and other process-mining vendors.

The larger, slower-burn issue is control of process data and interoperability. A customer perception that SAP tools are favored while third-party tools face data-access friction could raise switching and procurement scrutiny, although the US case is not yet a near-term catalyst. Litigation could also cut both ways: SAP’s counterclaims make a clean, durable competitive victory for Celonis less certain. Over 1–3 months, watch for appeal or patent-validity developments and evidence of customer disruption; over 6–18 months, monitor whether Signavio’s role in RISE packaging or migration activity changes. No verified financial impact is established here.

Key Decisions for Investors

• Do not initiate a standalone short in SAP on this ruling alone. Treat it as a watch item; reassess if SAP discloses a material workaround, customer disruption, or a change in Signavio/RISE packaging or migration guidance.
• For existing SAP exposure, consider a limited-risk hedge only if subsequent court actions broaden the injunction or SAP links the dispute to migration delays. Falsifiers: a successful workaround, reversal on appeal, or invalidation of the asserted patent.
• Track customer and channel evidence rather than relying on either company’s claims: Signavio renewals and adoption, RISE conversion commentary, and procurement decisions involving independent process-mining tools. These would clarify whether the dispute is merely feature-level or is affecting competitive positioning.
• Keep Celonis on the potential beneficiary list, but do not infer a tradable public-equity proxy from this article; it provides no evidence of near-term revenue gains for GSK or Siemens.